Abstract: There has been insufficient evidence on whether exposure to hypnotics affects the risk of type 2 diabetes (T2DM). The aim of this study was to examine patients with nonapnea sleep disorders using zolpidem, benzodiazepines (BZDs), or a combination of both, and their risk of T2DM.
INTRODUCTION

E
pidemiological studies have shown that the prevalence of sleep disorders is approximately 25% to 37% of the general adult population in Asia. 1, 2 There is growing evidence that sleep plays a major role in the regulation of neuroendocrine function and metabolism in adults. Laboratory studies have found that sleep deprivation is related to glucose metabolism, which can reduce insulin sensitivity and increase insulin resistance or change the balance of orexins. 3, 4 Prior studies have found associations between sleep problems and chronic diseases, including cardiovascular disease, 5 hypertension, 6 and type 2 diabetes (T2DM), 7, 8 as well as an increased mortality from disease. 9, 10 Among sleep disorders, an increasing amount of study evidence suggests that sleep apnea syndrome or sleep-disordered breathing (SDB) is correlated with the prevalence and incidence of diabetes. 11, 12 The effect of sleep apnea on metabolism regulation aspects has been extensively examined and supported, but research on the association between nonapnea sleep disorder (NSD) and T2DM has been relatively scant. 8 Thus far, hypnotics have been employed as the mainline therapy for patients with NSDs. 13 They can be divided into benzodiazepines (BZDs) and nonbenzodiazepines (non-BZDs). Common adverse side effects include nausea, tiredness, weakness, dizziness, and confusion. 14, 15 Previous studies have reported that patients using hypnotics are associated with an increased risk of dementia, 16 stoke, 17 and of cancer. 18 Zolpidem is a widely used non-BZD hypnotic drug for treating insomnia. Prior studies have indicated correlations between the use of zolpidem and rising glucose concentrations, but the mechanism unclear. 19 Another study found that zolpidem caused sleep eating and a hyperglycemic state in patients with type 1 diabetes. 20 These findings are often restricted to specific sample sizes or case reports, limiting their possibilities for generalization. To date, few studies have explored the longterm effects of zolpidem on patients' glucose metabolism or risk of T2DM. Therefore, this study used the Taiwan National Health Insurance Research Database (NHIRD) to long-term track these characteristics. This study examined patients with NSDs using zolpidem as a treatment, and its correlation with an increased risk of diabetes; and patients with NSDs treated with a combination of different hypnotics (zolpidem and BZDs), and whether these have a synergistic effect on the risk of diabetes.
METHODS
Data Source
The Taiwanese government established a universal, singlepayer health insurance program in 1995, providing insurance coverage for more than 99% of the country's population (http:// www.nhi.gov.tw/). The National Health Research Institutes was mandated to establish and manage the NHIRD, which contains the annual original claims data for reimbursement. This retrospective cohort study used the Longitudinal Health Insurance Database (LHID), which consists of all the original claims data of 1 million beneficiaries randomly selected from the original 2000 registry for beneficiaries. To protect privacy, the identities of individuals included in the NHIRD were all encrypted. Diseases were identified in the NHIRD according to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). This study was exempted from full review by the institutional research ethics committee (CMU-REC-101-012).
Sampled Participants
Patients aged 20 years or older diagnosed with NSDs between 1997 and 2001 were identified from the LHID (ICD-9-CM 307.4 and 780.5, except sleep apnea syndrome [ICD-9-CM 780.51, 780.53, and 780.57]). The NSD patients were divided into 2 groups, according to their zolpidem use: the zolpidem group included patients who had received zolpidem therapy, whereas the nonzolpidem group included patients who had not received zolpidem therapy during follow-up. We excluded patients with a history of type 1 or type 2 diabetes (ICD-9-CM 250), or with incomplete age or sex information. For the non-NSD control group, we randomly selected patients without a history of NSDs, sleep apnea syndrome, or zolpidem, and applied the same exclusion criteria as in the NSD group. The NSD and non-NSD patients were frequency matched by age (5-year spans), sex, and year of NSD diagnosis. OUTCOME All study participants were followed up from the index date until the onset of T2DM (ICD-9-CM 250.Â0 and 250.Â2), withdrawal from the National Health Insurance (NHI) program, or the end of 2011.
Comorbidities and Medications
Baseline comorbidities included hypertension (ICD-9-CM 401-405), hyperlipidemia (ICD-9-CM 272), stroke (ICD-9-CM 
Statistical Analysis
Chi-squared and t-tests were used to evaluate the distributions of categorical and continuous variables between the NSD and non-NSD groups. The incidence densities of DM were calculated by sex, age, comorbidity, and BZD. Univariable and multivariable Cox proportional hazards regression models were used to determine the risk of developing DM, shown as a hazard ratio (HR) with a 95% confidence interval (CI). Multivariable analysis included the variables sex, age, comorbidity status, and medication with BZDs. For additional analyses the effect of the zolpidem medication cumulative duration and zolpidem medication cumulative dosage were also estimated. For zolpidem, the cumulative duration and cumulative dosage were divided into 3 levels on the basis of the dosage median and third quartile. All statistical analyses were performed using the SAS statistical package (Version 9.2 for Windows; SAS Institute, Inc., Cary, NC). A 2-tailed P < 0.05 was considered significant.
RESULTS
We identified 45,602 patients with NSDs (30,511 patients using zolpidem and 15,091 patients without zolpidem) and 40,799 patients in the non-NSD control group (Table 1) . The majority of patients were aged 41 to 65 years (50.3%, 43.7%, and 48.0% in the zolpidem, nonzolpidem, and non-NSD groups, respectively). Females accounted for more than half of the patients in each group. Compared with those in the non-NSD group, the comorbidities of hypertension, hyperlipidemia, stroke, CAD, and depression, as well as BZD use were more prevalent in the NSD group. The average follow-up duration was 9.01 years for patients using zolpidem, 9.00 years for patients without zolpidem use, and 8.98 years for non-NSD patients (data not shown). Overall, the incidence of T2DM was higher in the zolpidem and nonzolpidem groups than in the non-NSD control group (20.1, 12.5, and 11.9 per 1000 person-year, respectively) ( Table 2) . Compared with the non-NSD control group, NSD patients using zolpidem (adjusted HR ¼ 1.41, 95% CI ¼ 1.35-1.48) were associated with a significantly higher risk of developing T2DM. The T2DM incidence was greater in males than in females and increased with age in all the zolpidem, nonzolpidem, and non-NSD control groups. Male NSD patients in the nonzolpidem group (adjusted HR ¼ 1.11, 95% CI ¼ 1.02-1.22) were associated with a higher risk of developing T2DM compared with the non-NSD male controls. The risk of T2DM in NSD patients using zolpidem was higher than in non-NSD patients for all age groups. NSD patients using zolpidem also had a higher risk than non-NSD patients, whether with or without comorbidity. The BZD-specific-zolpidem group to control group adjusted HR of T2DM was significant for both patients without BZD use (adjusted HR ¼ 1.41, 95% CI ¼ 1.34-1.48) and patients with BZD use (adjusted HR ¼ 1.52, 95% CI ¼ 1.34-1.72). Table 3 shows that the overall risk of T2DM was 1.45 times higher in NSD patients using zolpidem than in NSD patients without zolpidem use (adjusted HR ¼ 1.45, 95% CI ¼ 1.38-1.54). The sex-specific relative risk of T2DM in NSD patients using zolpidem versus nonzolpidem NSD patients was significantly higher for both females and males. The risk of T2DM in NSD patients using zolpidem was higher than in nonzolpidem NSD patients regardless of age group, comorbidity status, or BZD use. 
DISCUSSION
The results of this study show that after adjustment for potential confounders (age, sex, comorbidities, and hypnotics), NSD patients using zolpidem have a 45% and 41% higher risk of T2DM compared with NSD patients without zolpidem use and patients with neither NSDs nor the use of hypnotics, respectively (Tables 2 and 3 ). The present study found that a strong correlation exists between the use of zolpidem and an increased risk of T2DM. In addition, in Table 4 , the NSD groups that used only zolpidem or only BZDs had a 48% and 26% higher risk of T2DM, respectively, compared with the reference group (patients without zolpidem or BZD use); moreover, when both zolpidem and BZDs are used together, there is a 77% increased risk of T2DM. This indicates that the use of both zolpidem and BZDs by NSD patients reflects an increased risk of T2DM; furthermore, the concomitant use of zolpidem with BZDs exhibits a joint effect on the patients' risk of T2DM. Based on our research, this is the first longitudinal populationbased study on the risk of T2DM associated with the use of zolpidem and different hypnotics in patients with NSDs.
Zolpidem is a frequently prescribed non-BZD hypnotic drug that enhances the effect of the gamma-aminobutyric acid neurotransmitter, whose receptor binds selectively onto the omega-1 receptor subtype. 13 Zolpidem therefore has a sedative hypnotic effect that lowers sleep latency and increases overall sleep time. 21 There is growing evidence that exposure to hypnotics could contribute to the development of different diseases such as dementia, stroke, and cancer. [16] [17] [18] However, research on the association between hypnotics and T2DM has been relatively scant. A previous study indicated that zolpidem use is related to the risk of acute pancreatitis; 22 patients who receive at least one prescription of zolpidem in 7 days have a 7-fold increased odds ratio for experiencing acute pancreatitis. The presenting or subtle pancreas damage could be a possible mechanism for zolpidem users developing diabetes.
In addition, a previous report on patients' intake of zolpidem and the occurrence of nocturnal sleep-related eating disorder (NSRED) and hyperglycemia revealed a chronological relationship. 23 Furthermore, another study found that NSRED led to a glucose-renewed state in patients using zolpidem; yet Patients with any one of the comorbidities (including hypertension, hyperlipidemia, stroke, CAD, and depression) were classified as the comorbidity group.
halting the use of zolpidem brought blood sugar levels back to normal. 20 These case reports showed that NSRED often followed after the use of zolpidem. Patients with NSRED are in a state of unconsciousness while preparing or eating a large amount of food; they have no memory of the night's activity upon waking. This results in weight gain or blood sugar instability, though the physiological mechanisms remain unknown. 23, 24 NSRED is considered a complex sleep behavior (CSB). Nonetheless, the use of high doses of zolpidem (>10 mg/day) is considered to increase the probability and the occurrence of CSBs. 25 Based on previous studies, 26 the prevalence of zolpidem inducing NSRED is considered to be 1%, and only a low number of patients develop it. Therefore, NSRED may be a risk factor associated with T2DM, but not the major cause of T2DM development in patients with zolpidem use.
As shown in Tables 2 and 3 , our study found that the use of BZDs or zolpidem is correlated with a significantly increased risk of diabetes, and that zolpidem users have a higher risk of developing diabetes than BZD users do. Although the main mechanism remains unclear for these results, we inferred potential mechanism from previous studies may provide some explanation. First, a previous study found that the use of BZDs (in particular, clonazepam) was related to changes in insulin secretion and sensitivity. 27 Another experimental study found that 15 days of zolpidem use followed by 15 days of consecutive BZD use resulted in a decrease in insulin sensitivity by 12% and 4%, respectively. 19 In addition, we understand that a conventional dose of any BZDs typically decreases the hypothalamicpituitary-adrenocortical cortex (HPA) axis activity. However, higher doses of BZDs could stimulate basal circulating corticosterone levels. 28 Second, zolpidem was reported to produce an exceptionally high increase in plasma adrenocorticotropic hormone and corticosterone concentrations compared with BZDs. 29 These biological theories could support the current findings that zolpidem users had a higher risk of developing y Hazard ratio mutually adjusted for age, sex, comorbidities of hypertension, hyperlipidemia, stroke, CAD, depression, and medication of benzodiazepines; Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001. diabetes than do BZD users because of an increase of HPA axis activity in patients taking drugs for an NSD.
Our study found that among NSD patients with zolpidem use, females and young adults ( 40 years) predominantly have a T2DM risk (Table 3) . We could not confirm the exact mechanism in these results. However, previous studies have indicated that a pharmacokinetic property of zolpidem is greatly affected by sex and age differences; for example, the zolpidem clearance rate has been lower in women than in men, which may contribute to the observed increased incidence of adverse drug reactions in women. 30, 31 Furthermore, a potential explanation that we could not rule out is that young adults tend to have fewer comorbidities and are more affected by zolpidem or NSDs. A previous study also found that among NSD patients, those younger than 40 years were more prone to have a T2DM risk than other age groups. 8 These findings regarding young adults require more attention, because previous studies have suggested that increased incidences of chronic diseases in young adults are associated with elevated mortality rates resulting from subsequent diseases. 32 As shown in Table 4 , when both zolpidem and BZDs are used together would have a higher risk for the users to develop diabetes than only zolpidem or only BZDs users. Therefore, the joint effect of zolpidem and BZD use is worthy of attention. In clinical treatments, over 50% of patients with NSD adopt a combined use of different types of hypnotics. 33 Previous studies have suggested that the combined use of hypnotics may increase the occurrence of adverse effects such as falling, bone fractures, and car accidents; 21, 34 however, no study has assessed the risks associated with diabetes. This study is the first to propose that the concomitant use of hypnotics results in an increased risk of diabetes. Although previous studies reported that BZDs or zolpidem are associated with increased blood sugar levels, the results have been limited to the observation of the shortterm use of 2 types of hypnotics on glucose metabolism. 19 It remains unclear whether the concomitant use of hypnotics poses a long-term impact on changes in glucose metabolism. Furthermore, we understand that the common side effects of hypnotic drugs, including muscle relaxation, drowsiness, and residual daytime effects, 14 may lead to a poor mental state and tiredness, which in turn reduce the willingness to perform daily activities. 35 Therefore, we could not rule out lower activity levels having a subsequent effect on the development of T2DM. Table 5 shows that extremely long-term zolpidem use, more than 60 days or more than 540 mg in cumulative dosage, paradoxically decreases the risk of developing diabetes. There are some possible explanations for this dramatic situation. First, generally, in patients with long-term use zolpidem, the severity of NSDs may be alleviated, and the adverse effects of NSDs decrease for diabetes risk. Second, a previous study found that patients with continuous zolpidem exposure were associated with adaptive changes in GABA-A receptors and were prone to develop tolerance. 36 However, in our study, we could not confirm the possible mechanism; because of the tolerance effects in the HPA axis, the specifically higher risk of diabetes would be eliminated if zolpidem is used for more than 60 days.
The cohort study design's strength is to use general population-based database (the NHIRD) including a very big sample-size under the Taiwan government's policy and operation. In addition, the health claims reimbursement is universal by only 1 buyer. Therefore, every insurance claim should be checked by the peer review of the medical specialists. However, there are still certain study limitations which remain possibly unmeasured or unknown confounding factors and are noteworthy potential biases that may compromise the results: no individual data such as lifestyles-habits, body weight-length, physical-exercise activity, socioeconomic conditions, and family histories in the NHIRD; level of evidence a retrospective cohort study is generally lower than a prospective cohort or randomized-controlled study to evaluate the relationship between zolpidem use and T2DM; the data in the NHIRD are primarily used to bill and are not validated to scientific researches; we could not confirm whether the patients prescribed with hypnotics had the truly drug intake behaviors.
To summarize, this is the first population-based retrospective cohort study using the Taiwan NHIRD to track patients with NSDs using zolpidem or BZDs and their relative risk of diabetes. The results show that the use of zolpidem or BZDs 
